BACKGROUND: Evidence regarding the correlation between smoking and breast cancer among young women is mixed, and previous studies have not assessed whether smoking is associated differentially with risks of the major breast cancer subtypes. METHODS: This was a population-based, case-control study of 778 women with estrogen receptor (ER)-positive breast cancers and 182 women with ER-negative, progesterone receptor-negative, and human epidermal growth factor receptor 2-negative (triple-negative [TN]), invasive breast cancers ages 20 to 44 years who were diagnosed from 2004 to 2010 in the Seattle-Puget Sound metropolitan area. A control group of 938 cancer-free women also was included. Associations between various aspects of smoking history and the risks of ER-positive and TN breast cancer were assessed using polytomous logistic regression. RESULTS: Ever-smokers had a 1.3-fold increased risk (95% confidence interval [CI], 1.1-fold to 1.7-fold increased risk) of breast cancer overall; and, when stratified by cancer subtype, they had a 1.4-fold increased risk (95% CI, 1.1-fold to 1.8-fold increased risk) of ER-positive breast cancer, but there was no elevation in their risk of TN disease (odds ratio, 1.1; 95% CI, 0.7-1.6). Current/recent smokers with a ≥10 pack-year history of smoking had a 1.6-fold increased risk (95% CI, 1.1-fold to 2.4-fold increased risk) of ER-positive breast cancer but had no increase in their risk of TN breast cancer (odds ratio, 1.0; 95% CI, 0.5-1.9). CONCLUSIONS: The current results suggested that young women who are current/recent smokers with high pack-year histories may have an increased risk of ER-positive breast cancer but not TN breast cancer. Although this association was modest, the findings suggest that an increased risk of ER-positive breast cancer may be another health risk incurred by young women who smoke.
BACKGROUND: Evidence regarding the correlation between smoking and breast cancer among young women is mixed, and previous studies have not assessed whether smoking is associated differentially with risks of the major breast cancer subtypes. METHODS: This was a population-based, case-control study of 778 women with estrogen receptor (ER)-positive breast cancers and 182 women with ER-negative, progesterone receptor-negative, and humanepidermal growth factor receptor 2-negative (triple-negative [TN]), invasive breast cancers ages 20 to 44 years who were diagnosed from 2004 to 2010 in the Seattle-Puget Sound metropolitan area. A control group of 938 cancer-free women also was included. Associations between various aspects of smoking history and the risks of ER-positive and TN breast cancer were assessed using polytomous logistic regression. RESULTS: Ever-smokers had a 1.3-fold increased risk (95% confidence interval [CI], 1.1-fold to 1.7-fold increased risk) of breast cancer overall; and, when stratified by cancer subtype, they had a 1.4-fold increased risk (95% CI, 1.1-fold to 1.8-fold increased risk) of ER-positive breast cancer, but there was no elevation in their risk of TN disease (odds ratio, 1.1; 95% CI, 0.7-1.6). Current/recent smokers with a ≥10 pack-year history of smoking had a 1.6-fold increased risk (95% CI, 1.1-fold to 2.4-fold increased risk) of ER-positive breast cancer but had no increase in their risk of TN breast cancer (odds ratio, 1.0; 95% CI, 0.5-1.9). CONCLUSIONS: The current results suggested that young women who are current/recent smokers with high pack-year histories may have an increased risk of ER-positive breast cancer but not TN breast cancer. Although this association was modest, the findings suggest that an increased risk of ER-positive breast cancer may be another health risk incurred by young women who smoke.
Authors: Tongzhang Zheng; Theodore R Holford; Shelia H Zahm; Patricia H Owens; Peter Boyle; Yawei Zhang; John Pierce Wise; Lisa Pleasants Stephenson; Francis Ali-Osman Journal: Cancer Causes Control Date: 2002-09 Impact factor: 2.506
Authors: Christopher I Li; Elisabeth F Beaber; Mei-Tzu Chen Tang; Peggy L Porter; Janet R Daling; Kathleen E Malone Journal: Breast Cancer Res Treat Date: 2012-12-09 Impact factor: 4.872
Authors: Wael K Al-Delaimy; Eunyoung Cho; Wendy Y Chen; Graham Colditz; Walter C Willet Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-03 Impact factor: 4.254
Authors: Peggy Reynolds; Susan Hurley; Debbie E Goldberg; Hoda Anton-Culver; Leslie Bernstein; Dennis Deapen; Pamela L Horn-Ross; David Peel; Richard Pinder; Ronald K Ross; Dee West; William E Wright; Argyrios Ziogas Journal: J Natl Cancer Inst Date: 2004-01-07 Impact factor: 13.506
Authors: S J London; G A Colditz; M J Stampfer; W C Willett; B A Rosner; F E Speizer Journal: J Natl Cancer Inst Date: 1989-11-01 Impact factor: 13.506
Authors: Michelle L Baglia; Linda S Cook; C Mei-Tzu; Charles Wiggins; Deirdre Hill; Peggy Porter; Christopher I Li Journal: Int J Cancer Date: 2018-07-26 Impact factor: 7.396
Authors: Eboneé N Butler; Jeannette T Bensen; Mengjie Chen; Kathleen Conway; David B Richardson; Xuezheng Sun; Joseph Geradts; Andrew F Olshan; Melissa A Troester Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-11-13 Impact factor: 4.254
Authors: Kathleen Conway; Sharon N Edmiston; Eloise Parrish; Christopher Bryant; Chiu-Kit Tse; Theresa Swift-Scanlan; Lauren E McCullough; Pei Fen Kuan Journal: Breast Cancer Res Treat Date: 2017-03-08 Impact factor: 4.872
Authors: Song-Yi Park; Julie R Palmer; Lynn Rosenberg; Christopher A Haiman; Elisa V Bandera; Traci N Bethea; Melissa A Troester; Emma Viscidi; Laurence N Kolonel; Andrew F Olshan; Christine B Ambrosone Journal: Carcinogenesis Date: 2016-04-07 Impact factor: 4.944
Authors: Eboneé N Butler; Chiu-Kit Tse; Mary Elizabeth Bell; Kathleen Conway; Andrew F Olshan; Melissa A Troester Journal: Cancer Causes Control Date: 2016-05-06 Impact factor: 2.506
Authors: Rebecca H Johnson; Carey K Anders; Jennifer K Litton; Kathryn J Ruddy; Archie Bleyer Journal: Pediatr Blood Cancer Date: 2018-08-28 Impact factor: 3.167